The director purchases are a modest vote of confidence following a strong earnings beat, but the dollar amount is too small to be a meaningful signal for a $147B company. Monitor for any additional insider buying at higher volumes or C-suite participation to confirm conviction. The earnings beat and raised guidance are the more material catalysts for the stock.
PFE drugs
PFE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $26.20entry
- T+1 · 3mo ago +2.14%α +1.53% · $26.76
- T+5 · 3mo ago +2.29%α +1.08% · $26.80
- T+20 · 2mo ago +9.95%α +9.35% · $28.81
- T+60 · 17d ago +16.49%α +18.16% · $30.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Pfizer directors, Ronald Blaylock and Mortimer Buckley, made open-market purchases totaling ~$1.96M on August 5, 2026, two days after the company reported a Q2 2026 adjusted EPS beat of $0.77 (+12.9% vs consensus) and raised full-year revenue guidance. The CEO's grant of 24 shares is a routine non-cash award. While the director purchases are a modest positive signal, the total dollar value is only ~0.001% of Pfizer's $147B market cap, making it trivial in scale and unlikely to move the stock.
Key Financial Metrics
Key Facts
- Two directors purchased ~$1.96M in open-market stock on August 5, 2026, at ~$25.50/share.
- Purchases occurred two days after Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat) and raised FY2026 revenue guidance by $500M.
- Total insider purchases represent ~0.001% of Pfizer's $147.1B market cap, trivial in scale.
- CEO Albert Bourla received a non-cash grant of 24 shares worth $600, no economic signal.
Financial Impact
~$1.96M in director open-market purchases, representing ~0.001% of market cap
Risk Factors
- Director purchases are small relative to market cap and may be routine portfolio adjustments, not conviction buys.
- GAAP net loss of $0.04/share due to $4.3B impairments tempers the adjusted EPS beat narrative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PFE-1786003622984 |
Track record
21 reports on PFE
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
- Oct 30, 202617d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Viewing Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers